sorafenib
bayer
[]
nrg/rtog 1112 locally adv, unresectable cp-a #hcc sbrt 27.5-50 gy x5 f/b sorafenib median os benefit 15.8 vs 12.3 mos w/sorafenib (noted 80 to 65% reduction in power due to amendment given new #1l systemic landscape) but imp shows role of multimodal tx (sbrt) in this space #gi23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope